Sensitivity of KRAS-Mutated Non-Small Cell Lung Cancer to a Combination of MEK Kinase Inhibitor (Trametinib) and Autophagy Inhibitor (Hydroxychloroquine) in a Tissue Explant Model. Voprosy onkologii, v. 72, n. 1, p. OF-2403, 11 Mar.2026.